Results 21 to 30 of about 32,902 (265)

Early genetic diagnosis of clarithromycin resistance in Helicobacter pylori. [PDF]

World J Gastroenterol, 2021
The drug resistance rate of clinical Helicobacter pylori (H. pylori) isolates has increased. However, the mechanism of drug resistance remains unclear. In this study, drug-resistant H. pylori strains were isolated from different areas and different populations of Chinese for genomic analysis.To investigate drug-resistant genes in H. pylori and find the
Li XH, Huang YY, Lu LM, Zhao LJ, Luo XK, Li RJ, Dai YY, Qin C, Huang YQ, Chen H.   +9 more
europepmc   +3 more sources

Pattern of Primary Resistance of Helicobacter pylori to Clarithromycin among Pediatric Patients from North-Eastern Romania

Children, 2023
Background: Helicobacter pylori antibiotic resistance has increased worldwide and affects the effectiveness of current therapies. The recommended first-line empiric treatment should be tailored to the local clarithromycin resistance rate.
Oana-Maria Rosu, Nicoleta Gimiga, Roxana Popescu, Ileana Ioniuc, Carmen Daniela Rusu, Tatiana Clipa, Diana-Maria Florea, Doina-Anca Pleșca, Alexandru Nemtoi, Elena Tataranu, Gabriela Stefanescu, Smaranda Diaconescu   +11 more
doaj   +1 more source

Pathophysiology of Antibiotic Resistance: Clarithromycin [PDF]

Canadian Journal of Gastroenterology, 2000
Resistance ofHelicobacter pylorito antibiotics ranges from 3% to 10% and may exceed these levels in some countries. The pathophysiology of clarithromycin resistance is reviewed, including the mode of action by which the antibiotic inhibits protein synthesis and the mechanism of resistance, which involves a mutation at position 2142 or 2143 in the V ...
openaire   +4 more sources

Bismuth-based quadruple therapy following H. Pylori eradication failures: A multicenter study in clinical practice [PDF]

, 2015
Background & Aims: Helicobacter pylori (H. pylori) eradication in patients who failed one or more therapeutic attempts remains challenging. This study aimed to assess the efficacy of three-in-one capsules bismuth-based quadruple therapy (Pylera®) in ...
Zullo, Angelo, De Francesco, Vincenzo, Bellesia, Annamaria, Vassallo, Roberto, D’angelo, Audenzio, Scaccianoce, Giuseppe, Sacco, Rodolfo, Bresci, Giampaolo, Eramo, Annarita, Tanzilli, Anna, Ridola, Lorenzo, Alvaro, Domenico, Londoni, Claudio, Brambilla, Gianfranco, Manta, Raffaele, Di Ciaula, Agostino, Portincasa, Piero   +16 more
core   +8 more sources

Europe's contribution to the evaluation of the use of systemic antimicrobials in the treatment of periodontitis

Periodontology 2000, EarlyView., 2023
Abstract This narrative review celebrates Europe's contribution to the current knowledge on systemically administered antimicrobials in periodontal treatment. Periodontitis is the most frequent chronic noncommunicable human disease. It is caused by dysbiotic bacterial biofilms and is commonly treated with subgingival instrumentation.
David Herrera, Arie Jan van Winkelhoff, Paula Matesanz, Katalina Lauwens, Wim Teughels   +4 more
wiley   +1 more source

Mycobacterium avium strains resistant to clarithromycin and azithromycin [PDF]

Antimicrobial Agents and Chemotherapy, 1993
Mycobacterium avium strains susceptible to clarithromycin and azithromycin contain mutants resistant to these macrolides with a frequency of 1.1 x 10(-10) to 1.2 x 10(-6). Cross-resistance between clarithromycin and azithromycin was demonstrated with mutants selected in the laboratory as well as with resistant strains isolated from patients.
L, Heifets, N, Mor, J, Vanderkolk
openaire   +2 more sources

Supra and subgingival application of antiseptics or antibiotics during periodontal therapy

Periodontology 2000, EarlyView., 2023
Abstract Periodontal diseases (gingivitis and periodontitis) are characterized by inflammatory processes which arise as a result of disruption of the balance in the oral ecosystem. According to the current S3 level clinical practice guidelines, therapy of patients with periodontitis involves a stepwise approach that includes the control of the patient ...
Elena Figuero, Jorge Serrano, Nicole Birgit Arweiler, Thorsten Mathias Auschill, Ali Gürkan, Gülnur Emingil   +5 more
wiley   +1 more source

Polymorphism of virulence genes and biofilm associated with in vitro induced resistance to clarithromycin in Helicobacter pylori

Gut Pathogens, 2023
Background Clarithromycin-containing triple therapy is commonly used to treat Helicobacter pylori infections. Clarithromycin resistance is the leading cause of H. pylori treatment failure. Understanding the specific mutations that occur in H.
Naim Asyraf Rosli, Anis Rageh Al-Maleki, Mun Fai Loke, Eng Guan Chua, Mohammed Abdelfatah Alhoot, Jamuna Vadivelu   +5 more
doaj   +1 more source

Comparison of omeprazole, metronidazole and clarithromycin with omeprazole/amoxicillin dual-therapy for the cure of Helicobacter pylori infection [PDF]

, 1998
In this randomized, multicenter trial, we evaluated the effectiveness and side effect profile of a modified omeprazole-based triple therapy to cure Helicobacter pylori infection.
Bayerdörffer, Ekkehard, Bolle, Karl-Heinz, Höchter, Wilhelm, Klann, Hermann, Krämer, Walter, Lehn, Norbert, Meining, Alexander, Miehlke, Stephan, Simon, Thomas, Sommer, Albrecht, Stolte, Manfred, Weingart, Josef   +11 more
core   +1 more source

Resistance to clarithromycin and genotypes in Helicobacter pylori strains isolated in Sicily [PDF]

, 2015
The resistance of Helicobacter pylori strains to clarithromycin is increasing in several developed countries and their association with a genetic pattern circulation has been variously explained as related to different geographical areas.
BONURA, Celestino, CALA', Cinzia, Camilleri, S., Carlo, E., FASCIANA, Teresa Maria Assunta, GIAMMANCO, Anna, Manganaro, M., MATRANGA, Domenica, SCARPULLA, Giuseppe   +8 more
core   +1 more source